{
    "nctId": "NCT04937309",
    "briefTitle": "Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea",
    "officialTitle": "Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea in Patients With Breast Cancer Receiving Anthracycline and Cyclophosphamide Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 338,
    "primaryOutcomeMeasure": "Percentage of patients with significant nausea after the first chemotherapy cycle",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) status 0 to 2\n* patient with breast cancer planned to receive Anthracycline and Cyclophosphamide chemotherapy\n* informed consent\n* compliance expected\n* social security affiliation\n\nExclusion Criteria:\n\n* nausea or vomiting 24h or less, before inclusion\n* Antiemetic drug intake in the last 72h before inclusion\n* Central nervous system metastasis\n* Daily alcohol intake\n* Prior chemotherapy\n* Cardiac arrythmia, severe heart failure\n* Device for sleep apnea\n* History of arterial or venous thrombosis, or thrombophlebitis\n* Vagotomy\n* Vagal stimulation ongoing\n* Skin disease on the stimulation zone\n* Cochlear implant next to the stimulation zone\n* Unable to use the vagal stimulation device due to left ear unusual shape\n* Pregnant or breastfeeding women, or women of childbearing age without effective contraception\n* Documented allergy or contraindication to one of the antiemesis drugs required in the study\n* Protected adults (individuals under guardianship by court order)\n* Unable to read or write",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}